We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical … expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is … the number of drugs to treat a disease, not the number of drug classes. Pharmaceutical innovation also reduced hospital …

effect on technology transfer (catching up with the technological frontier) as well as innovation (pushing the frontier …

incentives and (b) innovation effects of the proposed remedy. We discuss the economic basis for the Commission’s claims that … and argue that the effects on innovation are not unambiguously negative as Microsoft claim. We conclude with some general … implications of the case for anti-trust enforcement in high innovation sectors. …

innovation distinguishing between “dirty” (internal combustion engine) and “clean” (e.g. electric and hybrid) patents across 80 … tax-inclusive fuel prices. Furthermore, there is path dependence in the type of innovation both from aggregate spillovers … and from the firm's own innovation history. Using our model we simulate the increases in carbon taxes needed to allow …

Longitudinal, disease-level data are used to analyze the impact of pharmaceutical innovation on longevity (mean age at … pharmaceutical innovation increased mean age at death by 0.87 years (10.4 months)-—about 44% of the total increase in longevity … pharmaceutical innovation. The baseline estimate of the cost per life-year gained from pharmaceutical innovation in Greece is $17 …